System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD334 / FGFR4

4FR6D3 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
New 11-591-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
New 11-591-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD334 / FGFR4 (fibroblast growth factor receptor 4), a transmembrane tyrosine kinase, which is expressed in many tissues, such as in lung, kidney, muscle, heart, pancreas, intestine and other, acts as a receptor for several fibroblast growth factors, namely FGF1, FGF2, FGF6, FGF8, and FGF19. Interaction with these growth factors initiates in cell the signaling cascades leading to the mitogenesis and cell differentiation. Presence of CD334 Gly338Arg allele correlates with prognostic parameters in various cancer studies. CD334 plays multiple roles in the organism, including those of muscle regeneration, cholesterol-to-bile acid metabolism, or glucose homeostasis.

Specificity

The mouse monoclonal antibody 4FR6D3 reacts with CD334, the fibroblast growth factor receptor 4, which is an approximately 88 kDa receptor tyrosine kinase expressed in variety of tissues.

Regulatory Status

Immunogen

NIH 3T3 cells transfected with full length human CD334

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
  • Immunocytochemistry
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Partanen J, Mäkelä TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K: FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J. 1991 Jun;10(6):1347-54. [Abstract] [Full Text]
  • *Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, Alitalo K: Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J. 1992 Dec;11(12):4273-80. [Abstract] [Full Text]
  • *Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002 Feb 1;62(3):840-7. [Abstract] [Full Text]
  • *Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, Zhang ZF: Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006 Dec 4;95(11):1455-8. [Abstract] [Full Text]
  • *Zhao P, Caretti G, Mitchell S, McKeehan WL, Boskey AL, Pachman LM, Sartorelli V, Hoffman EP: Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem. 2006 Jan 6;281(1):429-38. [Abstract] [Full Text]
  • *Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL: FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes. 2007 Oct;56(10):2501-10. [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy